Frank Follmann

Forskningsområder

Min forskning er centreret omkring samspillet mellem immunsystemet og patogenet, specielt med henblik på at udvikle nye vacciner og diagnostik.
Herunder arbejdes med:

• Infektionsimmunologiske studier af naturlig erhvervet immunitet
• Identifikation af B and T celle antigener
• Vaccinedesign vha. genteknologi til at sammensætte komponenter fra bakterier eller virus
• Forskning i nye vaccinehjælpestoffer (adjuvanser) og alternative vaccinationsformer over slimhinden 

Ansvarsområder

• Afdelingschef for Afdeling for Infektionsimmunologi

Udvalgte publikationer

• Borges AH, Follmann F, Dietrich J. Chlamydia trachomatis vaccine development - a view on the current challenges and how to move forward. 2022 Expert Rev Vaccines.
• Olsen AW, Pal S, De La Maza L, Follmann F. 2020: Chlamydia Vaccines (book chapter). In Chlamydia: Edited by C Suetterlin, H Hegemann and M Tan: Caister Academic Press
• Olsen, A. W., Rosenkrands, I., Holland, M. J., Andersen, P., Follmann, F. 2021. A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars. NPJ Vaccines 6, 58.
• Abraham S, Juel HB, Bang P, Cheeseman HM, Dohn RB, Cole T, Kristiansen MP, Korsholm KS, Lewis D, Olsen AW, McFarlane LR, Day S, Knudsen S, Moen K, Ruhwald M, Kromann I, Andersen P, Shattock RJ, Follmann F. 2019. Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect Dis.
• Blakney AK, McKay PF, Christensen D, Yus BI, Aldon Y, Follmann F, Shattock RJ. 2019. Effects of cationic adjuvant formulation particle type, fluidity and immunomodulators on delivery and immunogenicity of saRNA. J Control Release 304:65-74
• Rose F, Karlsen K, Jensen PR, Jakobsen RU, Wood GK, Rand KD, Godiksen H, Andersen P, Follmann F, Foged C. 2018. Unusual Self-Assembly of the Recombinant Chlamydia trachomatis Major Outer Membrane Protein (MOMP)-based Fusion Antigen CTH522 into Protein Nanoparticles. J Pharm Sci doi:10.1016/j.xphs.2018.02.005

Alle publikationer: Frank Follmann's bibliography